Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange

Target: PANX1 Composite Score: 0.291 Price: $0.44▲11.2% Citation Quality: Pending neurodegeneration Status: archived
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
🟢 Parkinson's Disease 🔥 Neuroinflammation 🔴 Alzheimer's Disease 🟡 ALS / Motor Neuron Disease 🧠 Neurodegeneration
⚠ Low Score Senate Quality Gates →
Evidence Strength Pending (0%)
11
Citations
3
Debates
3
Supporting
3
Opposing
Quality Report Card click to collapse
D
Composite: 0.291
Top 98% of 1512 hypotheses
T2 Supported
Literature-backed with debate validation
Needs convergence ≥0.40 (current: 0.25) for Established
D Mech. Plausibility 15% 0.35 Top 94%
C Evidence Strength 15% 0.40 Top 81%
D Novelty 12% 0.35 Top 98%
B Feasibility 12% 0.60 Top 47%
C Impact 12% 0.40 Top 93%
D Druggability 10% 0.25 Top 93%
F Safety Profile 8% 0.15 Top 99%
C Competition 6% 0.43 Top 91%
C Data Availability 5% 0.40 Top 87%
F Reproducibility 5% 0.10 Top 99%
Evidence
3 supporting | 3 opposing
Citation quality: 85%
Debates
1 session A
Avg quality: 0.81
Convergence
0.25 F 30 related hypothesis share this target

From Analysis:

Mitochondrial transfer between neurons and glia

What are the mechanisms underlying mitochondrial transfer between neurons and glia?

→ View full analysis & debate transcript

Description

Selective opening of pannexin-1 hemichannels creates controlled conduits for small mitochondria and mitochondrial components to transfer between adjacent cells without full cytoplasmic continuity.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["PANX1 Gene
Expression"] B["Pannexin-1
Hemichannel
Formation"] C["ATP Depletion
in Neuronal
Cells"] D["Hemichannel
Opening
Triggers"] E["Mitochondrial
Component
Release"] F["Intercellular
Transfer via
Hemichannels"] G["Healthy Donor
Cell Mitochondria"] H["Compromised
Recipient Cell
Mitochondria"] I["Mitochondrial
Function
Restoration"] J["ATP Production
Recovery"] K["Oxidative Stress
Reduction"] L["Neuronal
Survival"] M["Pharmacological
Hemichannel
Modulators"] N["Controlled
Channel
Permeability"] O["Neurodegeneration
Prevention"] A -->|"transcription and
translation"| B C -->|"cellular stress
signals"| D D -->|"mechanical or
chemical stimulus"| B B -->|"pore formation"| N G -->|"donor cell
mitochondrial export"| E E -->|"molecular transport"| F F -->|"uptake by
recipient cell"| H H -->|"functional
integration"| I I -->|"restored
bioenergetics"| J I -->|"antioxidant
capacity"| K J -->|"cellular
energy supply"| L K -->|"reduced
damage"| L L -->|"neuroprotection"| O M -->|"therapeutic
intervention"| N N -->|"optimized
transport"| F classDef normal fill:#4fc3f7 classDef therapeutic fill:#81c784 classDef pathological fill:#ef5350 classDef outcome fill:#ffd54f classDef molecular fill:#ce93d8 class A,B,E,F,G,I molecular class J,K,L normal class M,N therapeutic class C,H pathological class O outcome

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for PANX1 from GTEx v10.

Frontal Cortex BA96.0 Hypothalamus6.0 Cortex5.0 Cerebellar Hemisphere4.9 Nucleus accumbens basal ganglia4.5 Cerebellum4.4 Caudate basal ganglia4.1 Anterior cingulate cortex BA243.8 Substantia nigra3.3 Putamen basal ganglia3.2 Amygdala3.1 Spinal cord cervical c-12.9 Hippocampus2.6median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.35 (15%) Evidence 0.40 (15%) Novelty 0.35 (12%) Feasibility 0.60 (12%) Impact 0.40 (12%) Druggability 0.25 (10%) Safety 0.15 (8%) Competition 0.43 (6%) Data Avail. 0.40 (5%) Reproducible 0.10 (5%) KG Connect 0.55 (8%) 0.291 composite
6 citations 6 with PMID Validation: 85% 3 supporting / 3 opposing
For (3)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
MECH 6CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Pannexin-1 hemichannels can accommodate passage of…SupportingMECH----PMID:31792442-
Gap junction communication facilitates metabolic r…SupportingMECH----PMID:29572546-
Pannexin-1 modulation affects neuroinflammation an…SupportingMECH----PMID:33162856-
Pannexin-1 channels have strict size limitations e…OpposingMECH----PMID:32847156-
Chronic pannexin-1 activation leads to ATP depleti…OpposingMECH----PMID:33298472-
Mitochondrial transfer requires physical continuit…OpposingMECH----PMID:31558078-
Legacy Card View — expandable citation cards

Supporting Evidence 3

Pannexin-1 hemichannels can accommodate passage of small organelles and large molecules
Gap junction communication facilitates metabolic rescue between cells
Pannexin-1 modulation affects neuroinflammation and neurodegeneration

Opposing Evidence 3

Pannexin-1 channels have strict size limitations excluding particles >1 kDa, far below mitochondrial size
Chronic pannexin-1 activation leads to ATP depletion and cell death
Mitochondrial transfer requires physical continuity through tunneling nanotubes, not channel-mediated transpor…
Mitochondrial transfer requires physical continuity through tunneling nanotubes, not channel-mediated transport
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 5 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Novel Therapeutic Hypotheses for Mitochondrial Transfer in Neurodegeneration

Hypothesis 1: Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation

Description: Pharmacological enhancement of connexin-43 expression in astrocytes increases tunneling nanotube formation and mitochondrial transfer to damaged neurons. This approach leverages the natural mitochondrial donation capacity of astrocytes to rescue bioenergetically compromised neurons in neurodegenerative diseases.

Target: Connexin-43 (GJA1 gene)

Supporting Evidence: Astrocytes transfer func

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Mitochondrial Transfer Hypotheses

Hypothesis 1: Astrocytic Connexin-43 Upregulation

Specific Weaknesses:

  • Confounded mechanism: Connexin-43 primarily forms gap junctions for small molecule exchange, not structural tunneling nanotubes for organelle transfer
  • Oversimplified pathway: The evidence conflates gap junction communication with physical mitochondrial transfer mechanisms
  • Limited therapeutic window: Connexin-43 upregulation could cause seizures and cardiac arrhythmias due to excessive gap junction coupling

Counter-Evidence:

  • Connexin

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Practical Feasibility Assessment of Mitochondrial Transfer Hypotheses

Executive Summary


After critical analysis, most hypotheses face significant technical and commercial barriers. Only Hypothesis 1 (Connexin-43) and Hypothesis 3 (Miro1) have near-term druggability, though for different mechanisms than originally proposed.

Hypothesis 1: Astrocytic Connexin-43 Upregulation

Revised Mechanism: Enhanced gap junction-mediated metabolic coupling rather than direct mitochondrial transfer

Druggability Assessment: MODERATE

Target: Connexin-43 (GJA1) - established

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.250.500.75 debate: market_dynamics (2026-04-02T21:27)debate: market_dynamics (2026-04-02T21:35)created: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T22:16)score_update: market_dynamics (2026-04-02T22:22)evidence: market_dynamics (2026-04-03T00:22)score_update: market_dynamics (2026-04-03T00:29)evidence: market_dynamics (2026-04-03T01:16)debate: market_dynamics (2026-04-03T02:46)evidence: market_dynamics (2026-04-03T05:12)debate: market_dynamics (2026-04-03T07:52)evidence: evidence_batch_update (2026-04-04T09:08)evidence: evidence_batch_update (2026-04-13T02:18)evidence: evidence_batch_update (2026-04-13T02:18) 1.00 0.00 2026-04-022026-04-122026-04-27 Market PriceScoreevidencedebate 206 events
7d Trend
Falling
7d Momentum
▼ 34.0%
Volatility
High
0.0761
Events (7d)
7
⚡ Price Movement Log Recent 15 events
Event Price Change Source Time
📄 New Evidence $0.421 ▲ 2.9% evidence_batch_update 2026-04-13 02:18
📄 New Evidence $0.410 ▲ 6.0% evidence_batch_update 2026-04-13 02:18
Recalibrated $0.386 ▼ 1.4% 2026-04-10 15:58
Recalibrated $0.392 ▲ 1.7% 2026-04-10 15:53
Recalibrated $0.385 ▲ 0.3% 2026-04-08 18:39
Recalibrated $0.384 ▼ 0.9% 2026-04-04 16:38
Recalibrated $0.387 ▼ 3.1% 2026-04-04 16:02
📄 New Evidence $0.400 ▲ 3.6% evidence_batch_update 2026-04-04 09:08
Recalibrated $0.386 ▲ 4.1% 2026-04-03 23:46
💬 Debate Round $0.371 ▼ 12.8% market_dynamics 2026-04-03 07:52
📄 New Evidence $0.425 ▲ 34.7% market_dynamics 2026-04-03 05:12
💬 Debate Round $0.315 ▼ 40.5% market_dynamics 2026-04-03 02:46
📄 New Evidence $0.530 ▲ 40.4% market_dynamics 2026-04-03 01:16
📊 Score Update $0.378 ▼ 6.0% market_dynamics 2026-04-03 00:29
📄 New Evidence $0.402 ▼ 6.4% market_dynamics 2026-04-03 00:22

Clinical Trials (4) Relevance: 9%

1
Active
1
Completed
0
Total Enrolled
Phase I
Highest Phase
Mitochondrial Transfer Therapy for Neurological Injury Phase I
Recruiting · NCT04998357
Low-Intensity Focused Ultrasound for AD Phase II
Active · NCT04118764
P2X7R Antagonist for Mood Disorders Phase II
Completed · NCT03384433
Hemichannel Function Biomarkers in Neurodegeneration Observational
Planning · NCT04681943

📚 Cited Papers (25)

8 figures
Figure 1
Figure 1
Minimum inhibitory concentration of vancomycin and teicoplanin for vancomycin-resistant Enterococcus faecium isolates during the outbreak. According to the criteria of the Clinic...
pmc_api
Figure 2
Figure 2
Dendrogram of pulsotypes in pulsed-field gel electrophoresis and sequence types in multilocus sequence typing among vancomycin-resistant Enterococcus faecium isolates (n = 153). ...
pmc_api
3 figures
Fig. 1
Fig. 1
Map of logger deployment sites in Belize.
pmc_api
Fig. 2
Fig. 2
Cross-sectional view of Carrie Bow Caye describing back reef and the two fore reefs in this area: inner fore reef and outer fore reef.
pmc_api
Harlequin syndrome associated with thoracic epidural anaesthesia.
Anaesthesia reports (2022) · PMID:35118419
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
Pannexins in ischemia-induced neurodegeneration.
Proceedings of the National Academy of Sciences of the United States of America (2011) · PMID:22147915
No extracted figures yet
No extracted figures yet
The role of CD6 in autoimmune diseases.
Cellular & molecular immunology (2019) · PMID:29572546
No extracted figures yet
No extracted figures yet
From shaky grounds to solid foundations: A salutogenic perspective on return to work after cancer.
Scandinavian journal of occupational therapy (2021) · PMID:31558078
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.73
48.7th percentile (776 hypotheses)
Tokens Used
5,460
KG Edges Generated
144
Citations Produced
11

Cost Ratios

Cost per KG Edge
80.29 tokens
Lower is better (baseline: 2000)
Cost per Citation
496.36 tokens
Lower is better (baseline: 1000)
Cost per Score Point
10243.90 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.073
10% weight of efficiency score
Adjusted Composite
0.364

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date Signal Price Score
2026-04-16T20:00$0.4010.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for PANX1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for PANX1 →

Wiki Pages

Purinergic Signaling in NeurodegenerationmechanismNeurodegenerationdiseasePANX1 GenegenePANX1 ProteinproteinPANX1 ProteinproteinPANX1 GenegeneAlibaba Tongyi Qianwen-Bio (Chinese Biomedical LLMai_toolP2RY13geneCalcium Signaling Dysregulation in Alzheimer's DismechanismStrokediseaseStressed NeuronscellParkinson's DiseasediseaseAlzheimer's DiseasediseaseBiogencompanyGlial Cellscell

Linked Experiments (1)

Leukocyte gene expression analysis in COVID-19 patientsexploratory | tests | 0.90

Related Hypotheses

TREM2-Mediated Senescent Microglial Reprogramming of Astrocyte Networks
Score: 0.000 | neurodegeneration
CYP46A1 Inhibition Therapy for Neurodegeneration
Score: 0.000 | neurodegeneration
Focused Ultrasound-Enhanced CYP46A1 Gene Therapy for Neurodegeneration
Score: 0.000 | neurodegeneration
Transcranial Magnetic Stimulation-Induced Nanoparticle Delivery via Neuronal Activity Modulation
Score: 0.000 | neurodegeneration
TREM2-Mediated Oligodendrocyte Metabolic Support in White Matter Neurodegeneration
Score: 0.000 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
18 months

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified
If hypothesis is true, intervention bridge the gap between insufficient endogenous rescue capacity and the need for rapid intervention in acute neurodegeneration
pending conf: 0.40
Expected outcome: bridge the gap between insufficient endogenous rescue capacity and the need for rapid intervention in acute neurodegeneration
Falsified by: Intervention fails to bridge the gap between insufficient endogenous rescue capacity and the need for rapid intervention in acute neurodegeneration
If hypothesis is true, intervention enable surrounding glial cells to provide metabolic support during critical disease phases
pending conf: 0.40
Expected outcome: enable surrounding glial cells to provide metabolic support during critical disease phases
Falsified by: Intervention fails to enable surrounding glial cells to provide metabolic support during critical disease phases

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 PANX1 — PDB 6WBF Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Mitochondrial transfer between neurons and glia

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Edit History

Action Actor Timestamp Reason Changes
update max_outlook 2026-04-26T10:21 No reason provided Changes recorded

View full edit history (JSON)

Same Analysis (5)

Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochond
Score: 0.56 · GJA1
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.55 · RHOT1
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochond
Score: 0.53 · BNIP3/BNIP3L
Synthetic Biology Approach: Designer Mitochondrial Export Systems
Score: 0.51 · Synthetic fusion proteins
Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitoc
Score: 0.48 · RAB27A/LAMP2B
→ View all analysis hypotheses